MXPA02012682A - Metodo para administrar bisfosfonatos. - Google Patents

Metodo para administrar bisfosfonatos.

Info

Publication number
MXPA02012682A
MXPA02012682A MXPA02012682A MXPA02012682A MXPA02012682A MX PA02012682 A MXPA02012682 A MX PA02012682A MX PA02012682 A MXPA02012682 A MX PA02012682A MX PA02012682 A MXPA02012682 A MX PA02012682A MX PA02012682 A MXPA02012682 A MX PA02012682A
Authority
MX
Mexico
Prior art keywords
bisphosphonates
osteoporosis
potent
months
periods
Prior art date
Application number
MXPA02012682A
Other languages
English (en)
Spanish (es)
Inventor
Zebulun D Horowitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26952565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02012682(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA02012682A publication Critical patent/MXPA02012682A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA02012682A 2000-06-20 2001-06-18 Metodo para administrar bisfosfonatos. MXPA02012682A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59713500A 2000-06-20 2000-06-20
US26768901P 2001-02-09 2001-02-09
PCT/EP2001/006850 WO2001097788A2 (en) 2000-06-20 2001-06-18 Method of administering bisphosphonates

Publications (1)

Publication Number Publication Date
MXPA02012682A true MXPA02012682A (es) 2003-04-25

Family

ID=26952565

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012682A MXPA02012682A (es) 2000-06-20 2001-06-18 Metodo para administrar bisfosfonatos.

Country Status (24)

Country Link
US (1) US8052987B2 (enExample)
EP (1) EP1296689B3 (enExample)
JP (2) JP4722375B2 (enExample)
KR (1) KR100864743B1 (enExample)
CN (1) CN1272013C (enExample)
AT (1) ATE304856T1 (enExample)
AU (2) AU7410901A (enExample)
BR (1) BR0111806A (enExample)
CA (1) CA2410201C (enExample)
CY (2) CY1113740T1 (enExample)
CZ (1) CZ301972B6 (enExample)
DE (1) DE60113537T3 (enExample)
DK (1) DK1296689T3 (enExample)
ES (2) ES2247123T7 (enExample)
HU (1) HU228400B1 (enExample)
IL (2) IL153229A0 (enExample)
MX (1) MXPA02012682A (enExample)
NO (1) NO330459B1 (enExample)
NZ (1) NZ523086A (enExample)
PL (1) PL203087B1 (enExample)
PT (1) PT1591122E (enExample)
SK (1) SK287278B6 (enExample)
TW (1) TWI289451B (enExample)
WO (1) WO2001097788A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
DK1296689T3 (da) 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
NZ528659A (en) * 2001-04-03 2005-02-25 Royal Alexandra Hosp Children A drug for use in bone grafting
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
BR0308901A (pt) 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
TWI344367B (en) * 2002-09-16 2011-07-01 Novartis Ag Use of zoledronic acid or a pharmaceutically acceptable salt or hydrate thereof in the preparation of a medicament for the treatment of osteoporosis post hip fracture
AU2003280373A1 (en) * 2002-10-15 2004-05-04 Novartis Ag Method of administering bisphosphonates
ES2530791T3 (es) 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
EP1709968A1 (en) * 2004-01-30 2006-10-11 Astellas Pharma Inc. P2x receptor inhibitor
ES2358269T3 (es) * 2004-08-23 2011-05-09 Teva Pharmaceutical Industries Ltd Forma cristalina del ibandronato sódico y procedimientos para su preparación.
WO2006062876A2 (en) * 2004-12-09 2006-06-15 Merck & Co., Inc. Estrogen receptor modulators
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2007124274A1 (en) * 2006-04-21 2007-11-01 The Uab Research Foundation Treating neoplasms
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100068211A1 (en) * 2008-02-08 2010-03-18 Bateman Ted A Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
KR101813728B1 (ko) * 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
DK2473172T3 (en) 2009-09-01 2015-06-15 Univ Duke BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
CN103623465B (zh) * 2013-11-21 2015-12-30 彭江 一种可局部调节成破骨活性的组织工程骨支架及制备方法
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
KR20180115979A (ko) 2017-04-14 2018-10-24 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
AU2019370565A1 (en) * 2018-11-02 2021-06-24 Ampersand Biopharmaceuticals, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers
KR102049233B1 (ko) * 2019-01-14 2019-11-28 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594329A (en) * 1897-11-23 Socket or collet
DE3232959A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Substituierte benzolsulfonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0381296B1 (en) 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
US4812304A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
HUT68010A (en) 1991-12-17 1995-05-29 Procter & Gamble Pharma The use of bisphonates and parathyroid hormone for the treatment of osteoporosis
ES2111163T3 (es) 1992-06-30 1998-03-01 Procter & Gamble Pharma Uso de fosfonatos para el tratamiento de la osteoporosis.
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (en) 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
US5366965A (en) 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
GB9408775D0 (en) 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
AU686019B2 (en) 1994-09-09 1998-01-29 Procter & Gamble Company, The Phosphonates and parathyroid hormone for osteoporosis
CA2199252A1 (en) 1994-09-09 1996-03-14 Ann Dunbar Geddes Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
ATE290871T1 (de) 1995-09-29 2005-04-15 Novartis Pharma Gmbh Verfahren zur behandlung navikularer krankheiten bei pferden
US5735810A (en) 1996-06-14 1998-04-07 Becton Dickinson And Company Device for the iontophoretic administration of bisphosphonates
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
DE69803291T2 (de) 1997-07-22 2002-08-08 Merck & Co Inc Methoden zur verhinderung von knochenresorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
EP1178810B8 (en) * 1999-05-21 2005-07-27 Novartis AG Use of bisphosphonic acids for treating angiogenesis
WO2001045636A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Pharmaceutical kit
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
DK1296689T3 (da) 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater

Also Published As

Publication number Publication date
CN1620300A (zh) 2005-05-25
NO20026117D0 (no) 2002-12-19
DK1296689T3 (da) 2005-11-28
ES2394211T3 (es) 2013-01-23
PL203087B1 (pl) 2009-08-31
CY1113740T1 (el) 2015-08-05
NO20026117L (no) 2002-12-19
EP1296689A2 (en) 2003-04-02
WO2001097788A2 (en) 2001-12-27
CN1272013C (zh) 2006-08-30
SK287278B6 (sk) 2010-05-07
EP1296689B3 (en) 2013-02-13
DE60113537T2 (de) 2006-06-29
ES2247123T7 (es) 2013-03-01
EP1296689B1 (en) 2005-09-21
DE60113537T3 (de) 2013-05-29
HU228400B1 (en) 2013-03-28
HUP0301164A3 (en) 2005-11-28
CA2410201A1 (en) 2001-12-27
SK18082002A3 (sk) 2003-08-05
AU2001274109B2 (en) 2004-12-23
DE60113537D1 (de) 2006-02-02
TWI289451B (en) 2007-11-11
CY2013011I2 (el) 2015-08-05
CA2410201C (en) 2010-10-26
NO330459B1 (no) 2011-04-18
NZ523086A (en) 2007-07-27
JP2003535889A (ja) 2003-12-02
IL153229A0 (en) 2003-07-06
PT1591122E (pt) 2012-12-12
ES2247123T3 (es) 2006-03-01
CY2013011I1 (el) 2015-08-05
WO2001097788A3 (en) 2002-06-27
JP4722375B2 (ja) 2011-07-13
JP2005247873A (ja) 2005-09-15
CZ301972B6 (cs) 2010-08-18
KR100864743B1 (ko) 2008-10-22
IL153229A (en) 2007-07-24
HK1072539A1 (en) 2005-09-02
BR0111806A (pt) 2003-05-20
US20030181421A1 (en) 2003-09-25
AU7410901A (en) 2002-01-02
CZ20024134A3 (cs) 2003-06-18
JP5005188B2 (ja) 2012-08-22
US8052987B2 (en) 2011-11-08
ATE304856T1 (de) 2005-10-15
KR20030015283A (ko) 2003-02-20
PL358224A1 (en) 2004-08-09
HUP0301164A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
WO2001097788A3 (en) Method of administering bisphosphonates
NZ527157A (en) Compositions for delivering bisphosphonates
DK0756484T3 (da) Vådgranuleringsformulering til diphosphonsyrer
DK0637236T3 (da) Farmaceutisk præparat og fremgangsmåde til dets fremstilling
CY1106482T1 (el) Φαρμακευτικη παρεντepικη συνθεση πepιεχοντας ενα διφωσφονικο
NZ514478A (en) A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
WO2001076577A3 (en) Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
MY140080A (en) Treatment and prevention of osteoporosis
EA004544B2 (ru) Способ ингибирования резорбции костей
DK1178810T3 (da) Anvendelse af bisphosphonsyrer til behandling af angiogenese
EA199700183A1 (ru) Способ уменьшения риска невертебральных переломов костей
WO2001091738A3 (en) Naaladase inhibitors for treating amyotrophic lateral sclerosis
IL139966A0 (en) Medicaments containing bisphosphonic acids and derivatives thereof which are provided for preventing and treating autoimmune disease and allergies
ES2152865A1 (es) Utilizacion de bisfosfonatos en la preparacion de composiciones farmaceuticas para uso intramuscular.
TH158917A (th) วิธีการบริหารบีสฟอสฟอเนต

Legal Events

Date Code Title Description
FG Grant or registration